Table 3 Results after 3 months of follow up (V4).

From: Fasting mimicking diet cycles versus a Mediterranean diet and cardiometabolic risk in overweight and obese hypertensive subjects: a randomized clinical trial

 

FMD

MD

FMD vs. MD

Estimate

Std. Error

P-value

Estimate

Std. Error

P-value

Estimate

Std. Error

P-value

Weight (lbs)

−5.4

1.9

0.006196

−10.4

1.7

7.02E-07

−4.7

2.9

0.107374

Waist circumference (inches)

−0.8

0.3

0.01946

−1.2

0.3

0.000618

−0.3

0.5

0.51075

BMI (kg/m²)

−0.8

0.3

0.024116

−1.8

0.3

1.05E-07

−1.0

0.4

0.022766

Fat%

−1.0

0.6

0.101736

−1.4

0.7

0.041597

−0.4

0.9

0.626997

Fat mass (lbs)

−4.6

1.7

0.012176

−7.1

1.9

0.000624

−2.5

2.5

0.332553

Trunk fat %

−0.7

0.6

0.235738

−1.5

0.7

0.037634

−0.7

0.9

0.434705

Trunk fat mass (lbs)

−1.8

0.9

0.04176

−3.6

1.1

0.002947

−1.7

1.4

0.236341

Fat free mass (lbs)

−0.9

1.5

0.546639

−4.7

1.3

0.000804

−3.9

1.9

0.049867

Sum legs muscle mass (lbs)

0.0

0.5

0.993048

−2.3

0.6

0.000456

−2.3

0.8

0.003228

RHI

−0.4

0.2

0.022259

0.0

0.1

0.934113

0.4

0.2

0.040603

RHI abnormal prevalence

1.0

0.6

0.077676

−0.1

0.6

0.873792

−1.1

0.8

0.133505

Heart rate (beats/min)

−0.3

2.0

0.87432

−2.1

2.3

0.371837

−1.5

3.0

0.613259

Systolic blood pressure (mmHg)

3.6

2.5

0.170322

−1.6

3.5

0.646739

−5.8

4.3

0.187445

Diastolic blood pressure (mmHg)

0.5

1.5

0.736755

−0.9

1.3

0.489266

−1.5

2.0

0.464687

C1 (or AC1) - Large artery elasticity index (ml/mmHgx10)

−0.1

0.8

0.913496

1.7

1.0

0.081858

1.8

1.3

0.157479

C2 (or AC2) - Small artery elasticity index (ml/mmHgx10)

0.3

0.5

0.545177

1.2

0.4

0.011089

0.9

0.7

0.220647

PULS score

−1.5

0.6

0.022492

−2.3

1.1

0.039072

−0.8

1.3

0.526924

Calculated heart age (years)

−2.6

1.5

0.091296

−1.9

1.1

0.090032

0.5

2.0

0.794108

Heart age difference

−3.0

1.5

0.04558

−3.0

1.1

0.012803

0.0

1.9

0.980291

MetSyn prevalence

0.0

0.7

0.978191

−0.6

0.8

0.417588

−0.6

1.0

0.55771

Diabetes prevalence

−3.0

2.4

0.213434

−14.2

4.4

0.001274

−5.0

4.3

0.240175

IL6 (pg/ml)

0.3

0.3

0.274541

0.0

0.5

0.976424

−0.3

0.6

0.599972

Leptin (pg/ml)

−4.6

0.9

7.52E-06

−5.7

1.3

9.12E-05

−1.1

1.5

0.4823

TNFalpha (pg/ml)

0.1

0.1

0.074772

0.3

0.2

0.21916

0.2

0.3

0.412241

High-sensitive CRP (mg/dL)

0.3

0.4

0.459005

−1.4

1.2

0.261142

−1.3

1.2

0.253096

Creatinine- urine, (mg/dL)

5.8

11.4

0.612214

11.5

11.0

0.301506

5.8

15.9

0.716799

LDL cholesterol (mg/dL)

−3.2

2.7

0.235695

−5.4

4.6

0.246857

−2.3

5.7

0.683612

HDL cholesterol (mg/dL)

−5.0

2.8

0.085307

−0.3

1.4

0.829028

5.1

3.2

0.108866

Triglycerides (mg/dL)

4.2

6.5

0.521597

−14.8

9.1

0.113515

−17.9

13.0

0.171995

Cholesterol-total (mg/dL)

−6.3

3.8

0.105568

−9.3

4.7

0.056773

−2.8

7.0

0.693429

Insulin (uU/ml)

−5.6

1.9

0.004583

−2.8

5.0

0.57171

2.8

5.2

0.590103

HbA1c (%)

−0.1

0.1

0.011585

−0.2

0.1

0.053807

−0.1

0.1

0.466932

IGF-1 (ng/ml)

−6.9

4.3

0.121432

−7.0

6.0

0.25169

0.0

7.4

0.997548

HOMA-IR

−1.5

0.5

0.006643

−1.6

1.4

0.256794

0.0

1.4

0.976463

Glucose (mg/dl)

−0.3

2.1

0.886894

−7.3

6.4

0.258733

−7.2

6.8

0.291929

  1. For each continuous outcome variable, linear mixed models were used to assess the effect of time and treatment. We used the t-test to calculate the p-value of the coefficient for each of the two groups. Group is included in the model to account for baseline differences in the outcome variable between treatment groups. The inclusion of time in the model allows for changes in the outcome over time that are unrelated to the intervention. The interaction terms provide estimates of the treatment effects over time, and the t-test for its coefficient was used to calculate the p-value comparing MD with FMD. Significant values are highlighted in boldface.
Back to article page